Global Bronchitis Treatment Market Size, Share, and COVID-19 Impact Analysis, By Type (Acute Bronchitis and Chronic Bronchitis), By Drug Class (Antibiotics, Anti-Inflammatory Drugs, Bronchodilators, Mucolytic), End User (Hospital Pharmacies, Retail Pharmacies, and Other End Users), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030Industry: Healthcare
Global Bronchitis Treatment Market Insights Forecasts to 2030
- The Global Bronchitis Treatment Market Size was valued at USD 6.2 billion in 2021.
- The market is growing at a CAGR of 5.2% from 2022 to 2030.
- The worldwide Bronchitis Treatment Market size is expected to reach USD 9.8 billion by 2030.
- Europe is expected to grow the fastest during the forecast period.
Get more details on this report -
The Global Bronchitis Treatment Market Size is expected to reach USD 9.8 billion by 2030, at a CAGR of 5.1% during the forecast period 2022 to 2030. Throughout the forecast, an increase in the market for bronchitis treatments is anticipated. A sizable patient pool is a significant driver of industry expansion.
A respiratory illness known as bronchitis causes inflammation in the lungs' bronchi. In other forms, bronchitis is an inflammation of the lining of the airways known as bronchial tubes. Common bronchitis signs and symptoms include coughing, exhaustion, shortness of breath, chest pain, and the production of mucus. Acute and chronic bronchitis are the two categories into which the condition of bronchitis has been classified. Acute inflammation of the airways caused by many different kinds of conditions, most frequently a viral infection, allergens, pollution, and others, is what causes acute bronchitis. Compared to acute bronchitis, which often develops after a respiratory infection like a cold and goes away in a week or two, chronic bronchitis is a more serious condition that progresses over time. Bronchitis is one of the most common respiratory illnesses seen both in industrialized and developing nations. The market for bronchitis treatments is anticipated to develop as a result of factors like smoking, bacterial infections, and frequent colds and flu.
This research report categorizes the global bronchitis treatment market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global bronchitis treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global bronchitis treatment market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.
Global Bronchitis Treatment Market Report Coverage
|Market Size in 2021:||USD 6.2 Billion|
|Forecast Period:||2021 - 2030|
|Forecast Period 2021 - 2030 CAGR:||5.2%|
|2030 Value Projection:||USD 9.8 Billion|
|Historical Data for:||2017 - 2020|
|No. of Pages:||225|
|Tables, Charts & Figures:||120|
|Segments covered:||By Type, By Drug Class, By End User By Region|
|Companies Covered:||AstraZeneca, Novartis AG, GlaxoSmithKline plc, Dr. Reddys Laboratories Ltd. Melinta Therapeutics, Sanofi Aventis, Boehringer Ingelheim International GmbH, Cipla Ltd., Lupin Ltd., Merck and Co. Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Cadila Healthcare Ltd., Akorn Inc., Lincoln Pharmaceuticals Ltd|
Get more details on this report -
A major factor driving the market is the existence of a sizable pool of targeted patients worldwide as a result of hazardous behavior like smoking. Also, the frequency of occurrences of acute bronchitis is directly related to the rapidly rising environmental pollution. When choosing a course of treatment for the patient, the causal component is crucial. Moreover, people are becoming more aware of the range of treatment alternatives that are offered on the market as a result of the increased penetration of modern technologies into society. The increase in the elderly population, which has an increased incidence of bronchitis, the rising prevalence of chronic obstructive pulmonary disease (COPD), an increase in the number of smokers, and rising levels of chemical pollutants are the main drivers of the market's expansion. For example, according to data from NHS Digital and the House of Commons 2022, 1.9% of the population, or about 1.17 million persons, in England had been diagnosed with COPD in 2020–2021.
The price of the drugs used to treat bronchitis is high, which significantly slowed down the market's expansion. Also, people from developing and underdeveloped countries cannot afford such cutting-edge medical treatments may hamper the market growth. Moreover, the most significant obstacle to the expansion of the market for treating bronchitis is the patent expiry of important medications. Furthermore, for the forecast period, other constraints such as low patient awareness, high research and development expenditures, and preference for other treatment options may also limit the market for bronchitis treatments in terms of revenue growth.
In 2021, the chronic bronchitis segment is dominating the market with the largest market share over the forecast period.
Based on the type, the bronchitis treatment market is segmented into acute bronchitis and chronic bronchitis. Among these, chronic bronchitis dominated the market over the forecast period due to the several circumstances that are prevalent in society and a major contributing element in the development of chronic bronchitis is an underlying medical condition. Also, one major trend-boosting opportunity in the bronchitis treatment market is the coordinated efforts made by all healthcare teams to enhance the results of pharmacological treatment for chronic bronchitis. Furthermore, several pollutants that are inhaled affect the respiratory tract, including hazardous chemicals and industrial pollutants, which have the potential to induce chronic bronchitis.
In 2021, the antibiotic segment is leading the market over the forecast period.
Based on the drug class, the bronchitis treatment market is bifurcated into different segments such as, antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytics. Among these, antibiotics the segment accounts for a major share due to almost all types of disorders antibiotics are the most widely used as over-the-counter medication and also, the low cost and easy availability of the drug type. In addition, antibiotics' effects on infections help in the treatment of infections or in enhancing symptoms that patients present to doctors more effectively.
The segment of bronchodilators led to the next largest segment owing to, these drugs helping to provide immediate relief to the patients by helping them to clear air passages and hence enabling them to breathe properly.
In 2021, the hospital pharmacies segment is dominating the market over the forecast period.
Based on the end users, the bronchitis treatment market is classified into hospital pharmacies, retail pharmacies, and others, the hospital pharmacies segment held the largest market share due to a large number of patients are attended in the premises of the hospital. Also, most of the population chooses to purchase their medications from hospital pharmacies and then have them checked by a doctor to eliminate any potential confusion.
Regional Segment Analysis of the bronchitis treatment market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is dominating the market with the largest market share during the forecast period
Get more details on this report -
North America accounts for the largest market share during the forecast period due to the high prevalence of bronchitis and the general public's understanding of health. These regional markets have been boosted by continuous bronchitis therapeutic research to decrease the disease's morbidity. The key driver propelling the growth of the bronchitis treatment market is the infrastructure that the government provides for healthcare services to the populace.
Europe is projected to be the second most appealing market for bronchitis treatment due to the rising prevalence of chronic diseases, increasing healthcare expenditure by the European Commission, and rising awareness in people regarding health.
The report offers the appropriate analysis of the key organizations/companies involved within the bronchitis treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Novartis AG
- GlaxoSmithKline plc
- Dr. Reddy's Laboratories Ltd.
- Melinta Therapeutics
- Sanofi Aventis
- Boehringer Ingelheim International GmbH
- Cipla Ltd.
- Lupin Ltd.
- Merck and Co. Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Cadila Healthcare Ltd.
- Akorn Inc.
- Lincoln Pharmaceuticals Ltd
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In February 2022, Zydus, a division of Cadila Healthcare, declared that its US subsidiary had gained both final and tentative permission from the US Food and Drug Administration to distribute roflumilast tablets with a 500-mcg strength. The tablets are recommended as a medication for individuals with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations to lower their risk of exacerbations.
- In February 2020, according to Pfizer Inc., azithromycin for the treatment of acute bronchitis and secondary infections of chronic respiratory disorders will continue to be tested.
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the Global Bronchitis Treatment Market based on the below-mentioned segments:
Global Bronchitis Treatment Market, By Type
- Acute Bronchitis
- Chronic Bronchitis
Global Bronchitis Treatment Market, By Drug Class
- Anti-Inflammatory Drugs
Global Bronchitis Treatment Market, By End Users
- Hospital Pharmacies
- Retail Pharmacies
Bronchitis Treatment Market, By Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?